Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population

Coronary Artery Disease

Volumn 25, Issue 3, 2014, Pages 242-246

  Ziaee, Shayan ^a   Kalayinia, Samira ^a   Boroumand, Mohammad A ^a   Pourgholi, Leyla ^a   Cheraghi, Sara ^a   Anvari, Maryam S ^a   Sheikhvatan, Mehrdad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

atrial natriuretic peptide; coronary artery disease; gene polymorphism

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYSTINE; THREONINE;

ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENSINI SCORE; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IRAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ATRIAL NATRIURETIC FACTOR; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84898542732     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0000000000000075     Document Type: Article

References (25)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
2. Goetze JP. Coronary artery disease, heart failure, and cardiac natriuretic peptides in the middle. Eur Heart J 2005; 26:2603-2604.
3. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733-741.
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-663.
5. Rubattu S, Barbato A, Marchitti S, Iacone R, Di Castro S, Evangelista A, et al. Determinants of N-terminal pro atrial natriuretic peptide plasma levels in a survey of adult male population from southern Italy. J Hypertens 2010; 28:1638-1645.
6. Barbato S, Sciarretta S, Marchitti S, Iacone R, Di Castro S, Stanzione R, et al. Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort. Int J Cardiol 2011; 152:245-246.
7. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, et al. Prediction of long term survival in chronic heart failure by multiple biomarker assessment. A 15-year prospective follow-up study. Clin Cardiol 2010; 33:700-707.
8. Makikallio AM, Makikallio TH, Korpelainen JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, et al. Natriuretic peptides and mortality after stroke. Stroke 2005; 36:1016-1020.
9. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33-50.
10. Ellis KL, Newton-Cheh C, Wang TJ, Frampton CM, Doughty RN, Whalley GA, et al. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol 2011; 50:695-701.
11. Levin E, Gardner D, Samson W. Natriuretic peptides. N Engl J Med 1998; 339:321-327.
12. Knowlton KU, Rockman HA, Itani M, Vovan A, Seidman CE, Chien KR. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium. J Clin Invest 1995; 96:1311-1318.
13. Gruchala M, Cieć wierz D,Wasag B, Targoń ski R, Dubaniewicz W, Nowak A, et al. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J 2003; 145:125-131.
14. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep 2009; 11:35-42.
15. Zhang I, Cheng L, He M, Hu B, Wu T. ANP T2238C, C-664G gene polymorphism and coronary heart disease in Chinese population. J Huazhong Univ Sci Technolog Med Sci 2006; 26:528-530.
16. Nsenga R, Cheng L, He M,Wu T. The role of natriuretic peptide precursor A gene polymorphism in the development of coronary heart disease in Chinese Han population. Front Med China 2009; 3:437-442.
17. Barbato E, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, Delrue L, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol 2012; 59:1763-1770.
18. Goetze JP, Gore A, Møller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18:1928-1930.
19. Chun YS, Hyun JY, Kwak YG, Kim IS, Kim CH, Choi E, et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003; 370:149-157.
20. Rastegar MA, Ve'gh A, Papp JG, Parratt Jr. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs. Cardiovasc Drugs Ther 2000; 14:471-479.
21. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25:227-234.
22. Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry GJ, et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 2004; 61:771-779.
23. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte- restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003; 111:1399-1407.
24. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMPdependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99:11363-11368.
25. Lynch AI, Boerwinkle E, Davis BR, Ford CE, Eckfeldt JH, Leiendecker-Foster C, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008; 299:296-307.